TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2021

Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.

Florian Lordick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.